Travere Therapeutics, Inc. (TVTX)
NASDAQ:TVTX
Want to see TVTX full AI Analyst Report?
TVTX Stock Chart & Stats
$40.77
-$0.11(-0.58%)
At close: 4:00 PM EST
$40.77
-$0.11(-0.58%)
Day’s Range― - ―
52-Week Range$13.97 - $55.11
Previous CloseN/A
Volume140.04K
Average Volume (3M)2.32M
Market Cap
$5.13B
Enterprise Value$5.28B
Total Cash (Recent Filing)$264.68M
Total Debt (Recent Filing)$327.66M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Jul 30, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding92,992,905
10 Day Avg. Volume2,133,077
30 Day Avg. Volume2,323,564
Financial Highlights & Ratios
PEG Ratio1.55
Price to Book (P/B)29.69
Price to Sales (P/S)6.95
P/FCF Ratio-167.32
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue9.85
Enterprise Value/Gross Profit10.49
Enterprise Value/Ebitda137.11
Forecast
1Y Price Target
$57.08Price Target Upside40.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.2
Revenue Forecast (FY)$699.18M
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone — FILSPARI Approved In FSGSThe FSGS approval creates durable first‑mover advantage in a previously unserved rare indication, expanding the labeled patient base and commercial runway. This structural change supports lasting physician adoption, formulary coverage efforts, and a materially larger addressable market for FILSPARI.
Strong Commercial Traction For FILSPARISustained high prescription starts, rapid YoY sales growth and broad payer access (~97% pathway noted elsewhere in the pack) indicate durable market penetration. Coupled with high gross margins, this level of demand underpins predictable revenue scaling as the FSGS label and broader awareness increase over quarters.
Improved Cash Generation And Funding HeadroomTransitioning from prior cash burn to positive operating and free cash flow provides ongoing funding for commercialization and pipeline activities without immediate reliance on dilutive capital. Combined with a cash and receivables pool cited elsewhere, this strengthens the company's ability to invest and execute over the next 2–6 months.
Bears Say
Elevated Leverage Limits Financial FlexibilityHigh net leverage constrains strategic optionality and increases refinancing and interest-rate exposure despite recent financings. Elevated debt amplifies downside risk if commercialization or reimbursement timelines slip, reducing capacity for opportunistic M&A or sustained heavy investment without raising additional capital.
GAAP Losses Persist Despite Non-GAAP GainsContinued GAAP losses mean the firm remains below consistent accounting profitability, which affects retained earnings and return-on-equity metrics. Sustained GAAP deficits can erode equity cushions and require continued operational improvement or higher sales durability to convert non-GAAP gains into permanent GAAP profitability.
Rising Operating Expenses And Royalty VolatilityMaterial increases in R&D and SG&A to support launches and trials, plus higher royalty charges and accounting shifts, structurally pressure operating margins and FCF unless revenue growth sustainably outpaces expense growth. This raises execution risk around hitting profit and cash targets over coming quarters.
Travere Therapeutics News
TVTX FAQ
What was Travere Therapeutics, Inc.’s price range in the past 12 months?
Travere Therapeutics, Inc. lowest stock price was $13.97 and its highest was $55.10 in the past 12 months.
What is Travere Therapeutics, Inc.’s market cap?
Travere Therapeutics, Inc.’s market cap is $5.13B.
When is Travere Therapeutics, Inc.’s upcoming earnings report date?
Travere Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 40 days.
How were Travere Therapeutics, Inc.’s earnings last quarter?
Travere Therapeutics, Inc. released its earnings results on May 04, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.158.
Is Travere Therapeutics, Inc. overvalued?
According to Wall Street analysts Travere Therapeutics, Inc.’s price is currently Undervalued.
Does Travere Therapeutics, Inc. pay dividends?
Travere Therapeutics, Inc. does not currently pay dividends.
What is Travere Therapeutics, Inc.’s EPS estimate?
Travere Therapeutics, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Travere Therapeutics, Inc. have?
Travere Therapeutics, Inc. has 92,992,905 shares outstanding.
What happened to Travere Therapeutics, Inc.’s price movement after its last earnings report?
Travere Therapeutics, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went down -0.245%.
Which hedge fund is a major shareholder of Travere Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.08 (40.01% Upside)
$57.08 (40.01% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
282.72%
12-Months-Change
Fundamentals
Return on Equity
-26.79%
Trailing 12-Months
Asset Growth
1.16%
Trailing 12-Months
Company Description
Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical firm headquartered in San Diego, California, was founded in 2008 with a mission to discover, develop, commercialize, and deliver treatments for rare diseases. The company adopted its current name in November 2020, previously operating as Retrophin, Inc. Its current product offerings include Chenodal, an orally administered synthetic form of chenodeoxycholic acid, used to dissolve radiolucent gallstones. Another key product is Cholbam, a cholic acid capsule prescribed for both children and adults suffering from bile acid synthesis disorders stemming from single enzyme defects, and as an auxiliary treatment for peroxisomal disorders. Additionally, Thiola and Thiola EC, tiopronin tablets, are available for managing homozygous cystinuria. In its development pipeline, Travere is advancing several therapeutic candidates. Sparsentan is currently in Phase III clinical trials, being investigated for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Also under development is TVT-058, a pioneering investigational human enzyme replacement candidate, which is undergoing Phase I/II clinical trials for classical homocystinuria. The company actively engages in strategic partnerships, holding a cooperative research and development agreement with the National Institutes of Health's National Center for Advancing Translational Sciences. It also collaborates with patient advocacy groups such as CDG Care and the Alagille Syndrome Alliance, collectively working towards identifying potential small molecule therapies for NGLY1 deficiency and Alagille syndrome.
TVTX Company Deck
TVTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and clinical momentum: a landmark FDA approval in FSGS, record demand and an 88% YoY increase in FILSPARI sales, encouraging pipeline progress (HARMONY restart with 2027 readout expectation), and improved non-GAAP profitability. Offsetting these positives are significant near-term cost increases (R&D and SG&A), higher royalty expense due to accounting changes, a continuing GAAP net loss, and some short-term revenue recognition/timing headwinds and education needs with physicians and payers. Overall, the positives (major approval, large sales growth, record demand, and clear runway to advance the pipeline) outweigh the near-term financial and operational challenges.View all TVTX earnings summariesTVTX Stock 12 Month Forecast
Average Price Target
$57.08
▲(40.01% Upside)
Technical Analysis
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
1.61% Insiders
39.64% Mutual Funds
37.39% Other Institutional Investors
6.14% Public Companies and
Individual Investors